HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
daunorubicin-DNA
complex of above two cpds to reduce toxicity of doxorubicin
Also Known As:
daunorubicin-DNA adduct; rubomycin-DNA complex
Networked:
9
relevant articles (
1
outcomes,
3
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Polycyclic Aromatic Hydrocarbons: 2020
Naphthacenes
Anthracyclines: 9423
Daunorubicin: 2641
daunorubicin-DNA: 9
Polycyclic Compounds: 6
Polycyclic Aromatic Hydrocarbons: 2020
Naphthacenes
Anthracyclines: 9423
Daunorubicin: 2641
daunorubicin-DNA: 9
Carbohydrates: 22023
Glycosides: 2119
Aminoglycosides: 5131
Anthracyclines: 9423
Daunorubicin: 2641
daunorubicin-DNA: 9
Nucleic Acids, Nucleotides, and Nucleosides: 1
Nucleic Acids: 11752
DNA: 145982
DNA Adducts: 2237
daunorubicin-DNA: 9
Genetic Phenomena
DNA Damage
DNA Adducts: 2237
daunorubicin-DNA: 9
Related Diseases
1.
Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/1982 - "
Daunorubicin-DNA complex in acute nonlymphoblastic leukemia.
"
01/01/1979 - "
Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: a preliminary report.
"
01/01/1981 - "
Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.
"
01/01/1979 - "
Forty-four adult patients under 60 years of age with acute nonlymphoblastic leukemia were randomized for induction treatment with one of the following three regimens: R 1 = courses of daunorubicin on day 1 + ARA-C on days 1--5; R 2 = courses of daunorubicin on days 1 and 2 + ARA-C on days 4--8; R 3 = courses of daunorubicin-DNA complex on days 1--2 + ARA-C on days 4--8. Out of 14 patients, 9 went into remission on R 1, 6 out of 14 on R 2, and 8 out of 16 on R 3. The preliminary results suggest that daunorubicin-DNA complex has the same efficacy for inducing remission as daunorubicin alone, if the same time intervals and dosages are used.
"
01/01/1979 - "
Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.
"
2.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
11/01/1974 - "
Daunorubicin-DNA: further clinical trials in acute non-lymphoblastic leukemia.
"
01/01/1979 - "
Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.
"
01/01/1979 - "
Treatment with daunorubicin-DNA (DNR-DNA) or adriamycin-DNA (ADM-DNA) has been evaluated in acute lymphoblastic leukemia of childhood (ALL), acute nonlymphoblastic leukemia (ANLL) and bronchogenic carcinoma (BC).
"
3.
Ehrlich Tumor Carcinoma
01/01/1979 - "
In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.
"
01/01/1979 - "
The antitumor effect of daunorubicin and of two preparations of daunorubicin-DNA complexes were compared in equitoxic doses against the Ehrlich ascites tumor and in a subline of this tumor resistant to daunorubicin.
"
4.
Bronchogenic Carcinoma
01/01/1979 - "
Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.
"
01/01/1979 - "
Treatment with daunorubicin-DNA (DNR-DNA) or adriamycin-DNA (ADM-DNA) has been evaluated in acute lymphoblastic leukemia of childhood (ALL), acute nonlymphoblastic leukemia (ANLL) and bronchogenic carcinoma (BC).
"
5.
Neoplasms (Cancer)
01/01/1993 - "
These daunorubicin-DNA adducts may not play a role in tumor induction because they were not detectable in vivo.
"
01/01/1993 - "
As part of an investigation of the mechanism of tumor induction by daunorubicin, the formation of daunorubicin-DNA adducts has been investigated by 32P-postlabeling assay.
"
01/01/1979 - "
The daunorubicin-resistant tumor was found to be cross resistant to both daunorubicin-DNA complexes.
"
01/01/1979 - "
The antitumor effect of daunorubicin and of two preparations of daunorubicin-DNA complexes were compared in equitoxic doses against the Ehrlich ascites tumor and in a subline of this tumor resistant to daunorubicin.
"
Related Drugs and Biologics
1.
Daunorubicin (Cerubidine)
2.
Cytarabine (Cytosar-U)
3.
doxorubicin-DNA
4.
DNA (Deoxyribonucleic Acid)